Cross-over study to investigate retinal function following administration of a single dose of AZD9056
Study identifier:D1520C00020
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study in Healthy Male Volunteers, to Investigate Retinal Function Following a Single 800mg Oral Dose of AZD9056
Medical condition
Rheumatoid Arthritis
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9056, Placebo
Sex
Male
Actual Enrollment
12
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jun 2008
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD9056 Oral tablet, 800mg, one single administration |
| Placebo Comparator: 2 | Drug: Placebo Single dose |
Contacts
Investigators
Principal Investigator
William Fahy
AstraZeneca Clinical Pharmacology Unit, Nottingham
